Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0MA9G
|
||||
| Former ID |
DNC006348
|
||||
| Drug Name |
3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528109] | ||
| Formula |
C17H17N
|
||||
| Canonical SMILES |
CCC1=C(CCC2=CC=CC=C21)C3=CN=CC=C3
|
||||
| InChI |
1S/C17H17N/c1-2-15-16-8-4-3-6-13(16)9-10-17(15)14-7-5-11-18-12-14/h3-8,11-12H,2,9-10H2,1H3
|
||||
| InChIKey |
ZKPVULIWDZEZIT-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 19 | Target Info | Inhibitor | [528109] | |
| 17 alpha-hydroxylase-C17, 20-lyase | Target Info | Inhibitor | [528109] | ||
| Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [528109] | ||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
| WikiPathways | Metapathway biotransformation | ||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Ovarian Infertility Genes | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| FSH signaling pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation | |||||
| Steroid Biosynthesis | |||||
| Glucocorticoid & Mineralcorticoid Metabolism | |||||
| Prostate Cancer | |||||
| Corticotropin-releasing hormone | |||||
| References | |||||